Arcturus Therapeutics
ARCT
23 hedge funds and large institutions have $9.16M invested in Arcturus Therapeutics in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.97% less ownership
Funds ownership: 5.21% → 4.24% (-0.97%)
20% less capital invested
Capital invested by funds: $11.5M → $9.16M (-$2.29M)
30% less funds holding
Funds holding: 33 → 23 (-10)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
83% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$305K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$82.2K |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$2.29K |
| 4 |
Two Sigma Investments
New York
|
+$805 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$233 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.39M |
| 2 |
Morgan Stanley
New York
|
-$288K |
| 3 |
VMI
VHCP Management II
New York
|
-$211K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$161K |
| 5 |
D.E. Shaw & Co
New York
|
-$158K |
ARCT Hedge Fund Activity: Q2 2017 in Review
23 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2017, worth a combined $9.16M — down 20% from $11.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ARCT and 2 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Panagora Asset Management, adding an estimated $305K. The largest seller was Broadfin Capital, exiting entirely with an estimated $1.39M sold.
- 23 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2017, down from 33 in Q1 2017.
- Funds reported $9.16M of Arcturus Therapeutics stock for Q2 2017, down 20% quarter-over-quarter.
- 2 funds opened new Arcturus Therapeutics positions in Q2 2017 and 12 closed out, a net change of -10 holders.
- The largest Arcturus Therapeutics buyer in Q2 2017 was Panagora Asset Management, an estimated $305K added.
- The largest Arcturus Therapeutics seller in Q2 2017 was Broadfin Capital, an estimated $1.39M sold.
Based on aggregated 13F filings for Q2 2017.